Et studie til at lære om studiemedicinen PF-08634404 i kombination med forskellige antikræftmidler ved fremskredne kræftformer
6. oktober 2026 opdateret af: Pfizer
EN ÅBEN INTERVENTIONSFASE 1B/2-STUDIE TIL VURDERING AF SIKKERHED, FARMAKOKINETIK OG FORLØBIG EFFEKT AF PF-08634404 I KOMBINATION MED FORSKILLIGE KRÆFTBEHANDLINGSSTOFFER HOS DELTAGERE MED AVANCEREDE SOLIDE TUMORER
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments.
To join in the study, participants must:
- Be 18 years or older
- Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread to other parts of the body
The study will look at:
- Whether PF-08634404 is safe to use with other cancer medicines.
- What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease.
- Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors.
The study has different parts, each testing PF-08634404 with a different cancer medicine:
- Part A will test PF-08634404 with a medicine called sigvotatug vedotin.
- Part B will test PF-08634404 with a medicine called PF-08046054/SGN-PDL1V
Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
162
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studiesteder
-
-
Arkansas
-
Fayetteville, Arkansas, Forenede Stater, 72703
- Rekruttering
- Highlands Oncology Group, PA
-
Rogers, Arkansas, Forenede Stater, 72758
- Rekruttering
- Highlands Oncology Group, PA
-
Springdale, Arkansas, Forenede Stater, 72762
- Rekruttering
- Highlands Oncology Group, PA
-
-
California
-
Fullerton, California, Forenede Stater, 92835
- Rekruttering
- Providence Medical Foundation
-
Fullerton, California, Forenede Stater, 92835
- Rekruttering
- Providence St. Jude Medical Center
-
Fullerton, California, Forenede Stater, 92835
- Rekruttering
- Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Scripps Green Hospital
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Scripps Clinic Torrey Pines (Scripps Cancer Center)
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Scripps Shiley Pavilion
-
Los Angeles, California, Forenede Stater, 90067
- Rekruttering
- Valkyrie Clinical Trials
-
Los Angeles, California, Forenede Stater, 90025
- Rekruttering
- START Los Angeles, LLC
-
Los Angeles, California, Forenede Stater, 90067
- Rekruttering
- Valkyrie Clinical Trials (Additional Site Pharmacy Storage Suite)
-
Los Angeles, California, Forenede Stater, 90067
- Rekruttering
- LACN Century City
-
Los Angeles, California, Forenede Stater, 90067
- Rekruttering
- Valkyrie Clinical Trials (Additional Site Suite)
-
Panorama City, California, Forenede Stater, 91402
- Rekruttering
- Mission Community Hospital (Satellite Site)
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80012
- Rekruttering
- Rocky Mountain Cancer Centers,LLP
-
Denver, Colorado, Forenede Stater, 80218
- Rekruttering
- Rocky Mountain Cancer Centers,LLP
-
Lone Tree, Colorado, Forenede Stater, 80124
- Rekruttering
- Rocky Mountain Cancer Centers,LLP
-
-
Florida
-
Coral Springs, Florida, Forenede Stater, 33065
- Rekruttering
- BRCR Medical Center Inc.
-
Land O' Lakes, Florida, Forenede Stater, 34638
- Ikke rekrutterer endnu
- Moffitt Cancer Center- Speros
-
Orange City, Florida, Forenede Stater, 32763
- Rekruttering
- Mid Florida Hematology and Oncology Center
-
Orlando, Florida, Forenede Stater, 32806
- Rekruttering
- Orlando Health Cancer Institute
-
Orlando, Florida, Forenede Stater, 32806
- Rekruttering
- Orlando Health Orlando Regional Medical Center
-
Orlando, Florida, Forenede Stater, 32806
- Rekruttering
- Orlando Health Ambulatory Care Center
-
Ruskin, Florida, Forenede Stater, 33570
- Ikke rekrutterer endnu
- Moffitt Cancer Center - SouthShore
-
Tamarac, Florida, Forenede Stater, 33321
- Rekruttering
- BRCR Global - Tamarac
-
Tampa, Florida, Forenede Stater, 33612
- Ikke rekrutterer endnu
- Moffitt Cancer Center
-
Tampa, Florida, Forenede Stater, 33607
- Ikke rekrutterer endnu
- Moffitt Cancer Center - International Plaza
-
Tampa, Florida, Forenede Stater, 33612
- Ikke rekrutterer endnu
- Moffitt Cancer Center - McKinley Campus
-
Tampa, Florida, Forenede Stater, 33612
- Ikke rekrutterer endnu
- Moffitt McKinley Hospital
-
Wesley Chapel, Florida, Forenede Stater, 33544
- Ikke rekrutterer endnu
- Moffitt Cancer Center - Wesley Chapel
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- Hackensack University Medical Center
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- John Theurer Cancer Center at Hackensack University Medical Center
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- Newman Street Imaging
-
Neptune City, New Jersey, Forenede Stater, 07753
- Rekruttering
- John Theurer Cancer Center at JSUMC
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Ikke rekrutterer endnu
- Robert Wood Johnson University Hospital
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Ikke rekrutterer endnu
- Rutgers Cancer Institute
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Ikke rekrutterer endnu
- Jack & Sheryl Morris Cancer Center
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Ikke rekrutterer endnu
- Robert Wood Johnson University Hospital (RWJBH)
-
Paramus, New Jersey, Forenede Stater, 07652
- Rekruttering
- John Theurer Cancer Center at From Road
-
Teaneck, New Jersey, Forenede Stater, 07666
- Rekruttering
- Heart Center Glenpointe
-
-
New York
-
The Bronx, New York, Forenede Stater, 10461
- Rekruttering
- Montefiore Medical Center- Montefiore Medical Park
-
-
Oregon
-
Eugene, Oregon, Forenede Stater, 97401
- Rekruttering
- Oncology Associates of Oregon, P.C.
-
-
Texas
-
Garland, Texas, Forenede Stater, 75042
- Rekruttering
- Dallas Cancer Specialists
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Southwest Oncology Associates
-
Houston, Texas, Forenede Stater, 77090
- Rekruttering
- Lumi Research
-
Irving, Texas, Forenede Stater, 75063
- Rekruttering
- US Oncology Investigational Products Center (IPC)
-
Sugar Land, Texas, Forenede Stater, 77479
- Rekruttering
- Voyage Clinical
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- Virginia Commonwealth University
-
Richmond, Virginia, Forenede Stater, 23219
- Rekruttering
- Virginia Commonwealth University
-
Richmond, Virginia, Forenede Stater, 23219
- Rekruttering
- VCU Medical Center Gateway Building
-
Richmond, Virginia, Forenede Stater, 23235
- Rekruttering
- VCU Health Stony Point
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- Massey Cancer Center Clinical & Translational Research Lab
-
South Hill, Virginia, Forenede Stater, 23970
- Rekruttering
- VCU Health Community Memorial Hospital
-
Tappahannock, Virginia, Forenede Stater, 22560
- Rekruttering
- VCU Health Tappahannock Hospital
-
-
-
-
Aquitaine
-
Bordeaux, Aquitaine, Frankrig, 33076
- Rekruttering
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
-
-
CÔTE D'OR
-
Dijon, CÔTE D'OR, Frankrig, 21079
- Rekruttering
- Centre Georges François Leclerc
-
-
Provence-Alpes-Côte d'Azur Region
-
Marseille, Provence-Alpes-Côte d'Azur Region, Frankrig, 13273
- Rekruttering
- Institut Paoli-Calmettes
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Frankrig, 75014
- Rekruttering
- Groupe hospitalier Paris saint Joseph
-
-
-
-
Pesaro AND Urbino
-
Fano, Pesaro AND Urbino, Italien, 61032
- Ikke rekrutterer endnu
- Azienda Sanitaria Territoriale Pesaro Urbino (AST PU)
-
-
ROME
-
Roma, ROME, Italien, 00144
- Ikke rekrutterer endnu
- IRCCS Istituto Nazionale dei Tumori Regina Elena
-
Roma, ROME, Italien, 00186
- Ikke rekrutterer endnu
- Ospedale Isola Tiberina - Gemelli Isola
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Rekruttering
- National Cancer Center Hospital East
-
-
Miyagi
-
Sendai, Miyagi, Japan, 9810914
- Ikke rekrutterer endnu
- Sendai Kousei Hospital
-
-
Osaka
-
Hirakata, Osaka, Japan, 573-1191
- Rekruttering
- Kansai Medical University Hospital
-
-
Shizuoka
-
Nagaizumi-cho, Shizuoka, Japan, 411-8777
- Rekruttering
- Shizuoka Cancer Center
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8677
- Rekruttering
- Tokyo Metropolitan Komagome Hospital
-
Bunkyo-ku, Tokyo, Japan, 113-8603
- Ikke rekrutterer endnu
- Nippon Medical School Hospital
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100730
- Rekruttering
- Peking Union Medical College Hospital
-
Beijing, Beijing Municipality, Kina, 100142
- Rekruttering
- Beijing Cancer hospital
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350014
- Rekruttering
- Fujian Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, Kina, 430030
- Rekruttering
- Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210029
- Ikke rekrutterer endnu
- Jiangsu Province Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Ikke rekrutterer endnu
- Fudan University Shanghai Cancer Center
-
Shanghai, Shanghai Municipality, Kina, 200030
- Rekruttering
- Shanghai Chest Hospital
-
-
Zhejiang
-
Taizhou, Zhejiang, Kina, 317000
- Rekruttering
- Taizhou Hospital of Zhejiang Province
-
-
-
-
-
Mayagüez, Puerto Rico, 00680
- Rekruttering
- Pan American Center for Oncology Trials, LLC - Mayaguez
-
Rio Piedras, Puerto Rico, 00935
- Rekruttering
- Pan American Center for Oncology Trials, LLC
-
San Juan, Puerto Rico, 00917
- Rekruttering
- BRCR Global Puerto Rico - Hato Rey
-
-
-
-
-
Cadiz, Spanien, 11009
- Rekruttering
- Hospital Universitario Puerta del Mar
-
Granada, Spanien, 18016
- Rekruttering
- Hospital Universitario San Cecilio
-
Jaén, Spanien, 23007
- Rekruttering
- Hospital Universitario de Jaen
-
Madrid, Spanien, 28040
- Rekruttering
- Hospital Clinico San Carlos
-
Málaga, Spanien, 29006
- Rekruttering
- Cadpet Malaga
-
Seville, Spanien, 41009
- Rekruttering
- Hospital Universitario Virgen Macarena
-
Seville, Spanien, 41009
- Rekruttering
- VIVO Capuchinos
-
-
Andalusia
-
Jaén, Andalusia, Spanien, 23007
- Rekruttering
- HT Médica Jaen LAs Nieves
-
-
Barcelona [barcelona]
-
Barcelona, Barcelona [barcelona], Spanien, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron
-
-
Catalunya [cataluña]
-
Barcelona, Catalunya [cataluña], Spanien, 08041
- Rekruttering
- Hospital de la Santa Creu i Sant Pau
-
-
Cádiz
-
Jerez de la Frontera, Cádiz, Spanien, 11407
- Rekruttering
- Hospital Jerez de la Frontera
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanien, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre
-
Madrid, Madrid, Comunidad de, Spanien, 280006
- Rekruttering
- Hospital Nuestra Señora del Rosario
-
-
Málaga
-
Málaga, Málaga, Spanien, 29010
- Rekruttering
- Hospital Universitario Virgen de la Victoria
-
Málaga, Málaga, Spanien, 29016
- Rekruttering
- Clínica Radiólogica Mario Gallegos
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Spanien, 46009
- Ikke rekrutterer endnu
- Fundación Instituto Valenciano de Oncología
-
-
-
-
-
Kaohsiung City, Taiwan, 807
- Rekruttering
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Kaohsiung City, Taiwan, 83301
- Rekruttering
- Chang Gung Memorial Hospital at Kaohsiung
-
Tainan, Taiwan, 704
- Rekruttering
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 100
- Rekruttering
- National Taiwan University Hospital
-
Taipei, Taiwan, 10449
- Rekruttering
- Mackay Memorial Hospital
-
Taipei, Taiwan, 11217
- Rekruttering
- Taipei Veterans General Hospital
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Tyskland, 79106
- Rekruttering
- Universitaetsklinikum Freiburg
-
-
Hesse
-
Frankfurt am Main, Hesse, Tyskland, 60488
- Rekruttering
- Krankenhaus Nordwest GmbH
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Tyskland, 40479
- Rekruttering
- Marien Hospital Düsseldorf
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Pathologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC and are not a candidate for complete surgical resection and curative concurrent/sequential chemoradiotherapy
- PD-L1 status available
- Part B only: PD-L1 ≥ TPS 1%
- Measurable disease based on RECIST v1.1 per investigator.
- Eastern Cooperative Oncology Group performance status of 0 or 1.
- Adequate organ function
Exclusion Criteria:
- Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET for which there are available first-line therapies per local standard-of-care (SOC)
- History of another malignancy within 2 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy
- Known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compression
- Leptomeningeal disease
- Active autoimmune diseases requiring systemic treatment within the past 2 years
- Previous systemic anti-tumor therapy for locally advanced or metastatic NSCLC
- Previous treatment with immunotherapy (exception is (neo)adjuvant or consolidation anti-PD-(L)1), ADCs containing MMAE payload, systemic anti-angiogenic therapy, or prior radiotherapy >30 Gy to the lung within 6 months of first dose of study intervention
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: PF-08634404 + PF-08046054/SGN-PDL1V (Part B)
Participants will receive PF-08634404 in combination with other anticancer agents as per protocol. |
-Concentrate for solution for infusion
Andre navne:
-Powder for concentrate for solution for infusion. Single use vial. |
|
Eksperimentel: PF-08634404 + Sigvotatug Vedotin (Part A)
Participants will receive PF-08634404 in combination with Sigvotatug Vedotin. |
-Concentrate for solution for infusion
Andre navne:
-Powder for concentrate for solution for infusion. Single use vial
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Through 90 days after the last study intervention; Up to approximately 5 years
|
AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through 90 days after the last study intervention; Up to approximately 5 years
|
|
Phase I: Number of participants with dose limiting toxicity (DLT)
Tidsramme: Through 90 days after the last study intervention; Up to approximately 5 years
|
Dose limiting toxicity based on dose limiting toxicity evaluable participants. The number of participants who experienced DLTs during the DLT observation period. |
Through 90 days after the last study intervention; Up to approximately 5 years
|
|
Phase 2: Confirmed Objective Response Rate (ORR) per RECIST v1.1 by investigator
Tidsramme: Up to approximately 5 Years
|
ORR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST v1.1. |
Up to approximately 5 Years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Antal deltagere med kliniske laboratorieafvigelser
Tidsramme: I op til 90 dage efter den sidste undersøgelsesintervention; Op til cirka 5 år
|
I op til 90 dage efter den sidste undersøgelsesintervention; Op til cirka 5 år
|
|
|
Phase I: Confirmed ORR per RECIST v1.1 by investigator
Tidsramme: Up to approximately 5 Years
|
ORR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST v1.1. |
Up to approximately 5 Years
|
|
Disease Control Rate (DCR) per RECIST v1.1 by investigator
Tidsramme: Up to approximately 5 years
|
DCR by investigator assessment is defined as the proportion of participants with CR or PR with confirmation, or Stable Disease (SD) by investigator assessment per RECIST version 1.1. |
Up to approximately 5 years
|
|
Duration of Response (DOR) per RECIST v1.1 by investigator
Tidsramme: Up to approximately 5 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first. |
Up to approximately 5 years
|
|
Progression Free Survival (PFS) per RECIST v1.1 by investigator
Tidsramme: Up to approximately 5 years
|
Progression-free survival is defined as the time from the date of randomization to the date of the first documentation of objective PD assessed by investigator per RECIST v1.1, or death due to any cause, whichever occurs first. |
Up to approximately 5 years
|
|
Pharmacokinetics (PK): Serum concentration of PF-08634404 with anticancer agents
Tidsramme: Up to 37 days after the last dose of treatment
|
To characterize the pharmacokinetics (PK) of PF-08634404 with anticancer agents. |
Up to 37 days after the last dose of treatment
|
|
Incidence of Anti-Drug Antibody (ADA) against PF-08634404 with anticancer agents
Tidsramme: Up to 37 days after the last dose of treatment
|
To characterize the immunogenicity of PF-08634404 with anticancer agents. |
Up to 37 days after the last dose of treatment
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival (OS)
Tidsramme: Up to approximately 5 years
|
Overall survival defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 5 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Studieleder: Pfizer CT.gov Call Center, Pfizer
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
30. januar 2026
Primær færdiggørelse (Anslået)
8. marts 2029
Studieafslutning (Anslået)
23. august 2033
Datoer for studieregistrering
Først indsendt
7. november 2025
Først indsendt, der opfyldte QC-kriterier
10. november 2025
Først opslået (Faktiske)
12. november 2025
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
8. oktober 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
6. oktober 2026
Sidst verificeret
1. oktober 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- C6461020
- 2025-523526-40-00 (Ctis)
- Symbiotic-Lung-20 (Anden identifikator: Pfizer)
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ja
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .